
Immunovant Inc (IMVT) Earnings Dates & Reports
Immunovant Inc (IMVT) Most Recent Earnings
Report Date
Period EndingQ2 2026
Est. EPS-$0.72
Actual EPS-$0.73
EarningsMiss
Immunovant Inc (IMVT) Earnings
View the latest Immunovant Inc (IMVT) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares
Immunovant Inc (IMVT) Earnings per Share (EPS) History
Signup for full accessBrowse free
Immunovant Inc (IMVT) Latest Earnings
The value each IMVT share was expected to gain vs. the value each share gained.
Immunovant Inc (IMVT) reported its most recent earnings on for Q2 2026, posting earnings per share (EPS) of -$0.73. This exceeded analysts' expectations of -$0.72 by 1.39%, marking a Miss.
For comparison, Immunovant Inc reported EPS of -$0.74 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.71.
Immunovant Inc (IMVT) Earnings History
Immunovant Inc (IMVT) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Immunovant Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Immunovant Inc (IMVT) Earnings FAQs
Immunovant Inc (IMVT) last reported earnings on Nov 10, 2025 for Q2 2026, posting an EPS of -$0.73, which Miss the estimate of -$0.72 by 1.39%.
For Q2 2026, Immunovant Inc (IMVT) reported an EPS of -$0.73, missing analysts' estimate of -$0.72 by 1.39%.
For Q2 2026, Immunovant Inc (IMVT) Miss expectations with an actual EPS of -$0.73 vs. an estimated EPS of -$0.72.
Following the last earnings report on Nov 10, 2025, Immunovant Inc (IMVT)'s stock price moved — from — to —.
The next Immunovant Inc (IMVT) earnings call is scheduled for Feb. 5, 2026, where executives will discuss financial results and outlook.